On Friday, Following Stocks were among the “Top 100 Gainers” of U.S. Stock Market: Credit Suisse Group AG (NYSE:CS), IGI, Laboratories, Inc. (NYSEMKT:IG), B2Gold Corp. (NYSEMKT:BTG), Verastem, Inc. (NASDAQ:VSTM)

Credit Suisse Group AG (NYSE:CS), with shares inclined 4.62%, closed at $26.47.

IGI, Laboratories, Inc. (NYSEMKT:IG), with shares jumped 7.50%, settled at $9.32.

B2Gold Corp. (NYSEMKT:BTG), with shares climbed 7.24%, and closed at $1.63.

Verastem, Inc. (NASDAQ:VSTM), surged 7.17%, and closed at $12.10, hitting new 52-week high of $12.35.

Latest NEWS regarding these Stocks are depicted underneath:

Credit Suisse Group AG (NYSE:CS)

Formerly on March 11, according to Credit Suisse Group AG (CS) Asset Administration, “Commodities were higher in February, largely driven by fundamental supply and demand factors.”

The Bloomberg Commodity Index Total Return performance was positive for the month, with 12 out of 22 Index constituents trading higher.

Credit Suisse Asset Administration observed the following:

Energy was the best performing sector, up 8.43%, with all constituents posting positive returns. Petroleum products and Brent Crude Oil led the sector higher amid raised expectations of production cuts going forward. Notably, Brent Oil outperformed WTI Oil after the US Energy Information Administration stated an raise in US supplies for the 12th successive week.

Agriculture raised 2.21%, led by Soybean Oil. Ongoing strikes in Brazil’s largest soybean producing region reduced export capability, increasing fears over a potential supply shortage.

Industrial Metals ended the period 1.13% higher, led by Copper, as reports of potentially more active fiscal policy out of China, counting further reductions in banks’ required reserve ratios and cutting of interest rates, coupled with positive preliminary Chinese manufacturing data raised demand expectations for base metals.

Livestock declined 2.66%. Lean Hogs reduced the most due to increased pork production and reduced export availability amid labor strikes at US West Coast ports throughout the month, causing local inventories to build.

Precious Metals ended the period 4.87% lower as concerns eased over a potential Greek exit from the Eurozone, reducing safe haven demand and dampening the appeal of precious metals.

Credit Suisse Group AG, together with its auxiliaries, provides various financial services to private, corporate, institutional, government clients, and high-net-worth individuals, in addition to affluent and retail clients worldwide.

IGI, Laboratories, Inc. (NYSEMKT:IG)

IGI, Laboratories, Inc. (IG), a New Jersey based specialty generic pharmaceutical corporation, presented at the 27th Annual ROTH Conference. The Conference took placed on March 8-11, 2015 at the Ritz-Carlton, Laguna Niguel, Dana Point, California.

Jason Grenfell-Gardner, CEO and President and Jenniffer Collins, Chief Financial Officer of IGI Laboratories, Inc. presented on Monday, March 9, 2015.

IGI Laboratories, Inc., a specialty generic pharmaceutical corporation, develops, manufactures, and markets topical formulations in the United States. It sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms under IGI label.

B2Gold Corp. (NYSEMKT:BTG)

Formerly on March 13, B2Gold Corp. (BTG), stated its operational and financial results for the fourth quarter and year ended December 31, 2014. The Corporation formerly released its 2014 gold production and proceed in addition to its production and cash cost guidance for 2015.

2014 Fourth Quarter Highlights:

• Record quarterly merged gold production of 111,804 ounces (or 118,963 ounces counting 7,159 ounces of pre-commercial production from Otjikoto in December)
• Record quarterly gold production at the Masbate Mine of 62,972 ounces
• Merged cash operating costs of $646 per ounce and all-in sustaining costs of $946 per ounce
• Gold proceed of $122.4 million on sales of 102,612 ounces at an average price of $1,193 per ounce
• Cash flow from operating activities of $38.6 million ($0.04 per share)
• Strong cash position of $133 million at year-end
• Achieved commercial production at the Otjikoto Mine on February 28, 2015
• Attainment of Papillon Resources Limited accomplished on October 3, 2014, resulting in the attainment of the high-quality Fekola Gold Project in Mali
• Fekola feasibility study underway with completion predictable in the second quarter of 2015
• Road construction and site earthworks commenced at the Fekola Project in February 2015.

2014 Full-Year Highlights:

• Record annual merged gold production of 384,003 ounces (or 391,162 ounces counting 7,159 ounces of pre-commercial production from Otjikoto in December)
• Record annual gold production at La Libertad Mine of 149,763 ounces
• Merged cash operating costs of $680 per ounce and all-in sustaining costs of $1,101 per ounce, both within the Corporation’s full-year 2014 guidance range
• Gold proceed of $486.6 million on record sales of 386,219 ounces at an average price of $1,260 per ounce
• Cash flow from operating activities of $113.7 million ($0.15 per share)
• 2015 outlook provides for strong production growth of about 35% to between 500,000 to 540,000 ounces of gold with cash operating costs per ounce decreasing.

B2Gold Corp. explores for and develops mineral properties in Nicaragua, the Philippines, Namibia, Burkina Faso, and Colombia. The corporation principally explores for gold, silver, and copper. It primarily holds a 100% interest in the Libertad mine, which comprises of an exploitation concession covering an area of 10,950 hectares and an exploration concession covering an area of 1,196 hectares located to the east of Managua, Nicaragua; and a 95% interest in the Limon mine property that covers an area of 12,000 hectares located to the Northwest of Managua.

Verastem, Inc. (NASDAQ:VSTM)

Verastem, Inc. (VSTM), declared data presentations at the 2015 American Association of Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA.

Verastem, Inc., a biopharmaceutical corporation, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.